Joshua Zeidner, MD, Publishes “ENHANCE-2 Study” on Magrolimab and Azacitidine for TP53-Mutated AML.
March 15, 2025
Joshua Zeidner, MD, an Associate Professor of Medicine and Chief of Leukemia Research, published a paper in the journal Blood. Titled “Magrolimab plus azacitidine vs physician’s choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study,” he looked at a global randomized phase 3 study in acute myeloid leukemia (AML). This...